U.S. restrictions on Chinese biotechnology could harm patients, argues editorial
By
The Economist
Summary
The article argues against U.S. efforts to restrict collaboration with China's biotechnology industry, framing it as an extension of the tech war that could harm patients. It highlights a proposed bill to amend the COINS Act to include Chinese biotech licensing, and calls for the FDA to disregard Chinese clinical-trial data. The piece contends that patients benefit from faster, cheaper treatments regardless of where they are invented, and that restricting Chinese biotech would ultimately hurt those who need life-saving medicines.
Source
bskyU.S. restrictions on Chinese biotechnology could harm patients, argues editorialecon.stKey quotes
· 3 pulledSomeone whose life is saved by a new medicine is unlikely to care whether it was invented at home or on the other side of the world.
America's policymakers have begun treating China's biotechnology industry as the next front in the tech war.
Patients benefit from faster, cheaper treatments, wherever they are invented
You might also wanna read
U.S. restrictions on Chinese biotech could harm patients, argues editorial
The article argues against U.S. efforts to restrict collaboration with China's biotechnology industry, framing it as an extension of the tec
economist.com·1d ago
China's Rise in Global Clinical Trials: Regulatory Reforms and US Competitiveness
Theo Jaffee and Gabriel Dickinson interview Cremieux about China's rapid ascent to global leadership in clinical trial output. The discussio
pca.st·16h ago
NIH and NASA impose new restrictions on international research collaborations, causing confusion among scientists
U.S. government research funders, including the NIH and NASA, have imposed unprecedented restrictions on U.S. scientists collaborating and p
science.org·24d agoNIH and NASA impose new restrictions on international research collaborations, causing confusion among scientists
U.S. government research funders, including the NIH and NASA, have imposed unprecedented restrictions on U.S. scientists collaborating and p
science.org·24d ago
AI industry leaders unite to urge US lawmakers on bioweapon safeguards
AI industry rivals including Anthropic's Dario Amodei, OpenAI's Sam Altman, and Microsoft's Mustafa Suleyman have united in an open letter t
The Verge·18d agoAI industry leaders unite to urge US lawmakers on bioweapon safeguards
AI industry rivals including Anthropic's Dario Amodei, OpenAI's Sam Altman, and Microsoft's Mustafa Suleyman have united in an open letter t
theverge.com·18d ago
Inside the Grey Market Peptide Economy: Regulatory Gaps and Underground Pharmaceutical Infrastructure
This article investigates the parallel pharmaceutical infrastructure built around grey market peptides like BPC-157 and semaglutide. It cont
vectorculture.substack.com·5mo ago
U.S. Government Considers Ban on TP-Link Networking Equipment Over China Security Concerns
The U.S. government is reportedly preparing to ban the sale of TP-Link networking equipment, citing national security concerns related to th
Comments
Sign in to join the conversation.
No comments yet. Be the first.